TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6820076
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition regimen with lipid emulsion
Study: 6820076
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition regimen without lipid emulsion
Study: 31151800
Drug: 0.3 mL
Normalized name: ethanol 0.3 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mL of GC1109
Study: 31151800
Drug: 0.5 mL
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL of GC1109
Study: 31151800
Drug: 1.0 mL
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mL of GC1109
Study: 31151800
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline 0.5 mL)
Study: 26242443
Drug: Continuous diclofenac
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous diclofenac (150 mg/day)
Study: 26242443
Drug: Continuous diclofenac
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous diclofenac (150 mg/day) in C reactive protein positive or syndesmophytes patients
Study: 26242443
Drug: Continuous diclofenac
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous diclofenac (150 mg/day) in patients with syndesmophytes
Study: 15240611
Drug: hPTH (1-34)
Normalized name: (LEU27)-CYCLO(GLU22-LYS26)-HPTH-(1-31)-NH2
Approvals — FDA: no, EMA: no, PMDA: no
Description: hPTH (1-34) 400 U daily for 12 months
Study: 9572541
Drug: Loteprednol etabonate
Normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loteprednol etabonate (LE), n=10, instilled one drop into each eye 8 times daily on Days 0 and 1 and four times daily on Days 2 through 42
Study: 9572541
Drug: Placebo, n=4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, n=4, instilled one drop into each eye 8 times daily on Days 0 and 1 and four times daily on Days 2 through 42
Study: 2450751
Drug: Flecainide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (150 mg b.i.d.)
Study: 2450751
Drug: Propafenone (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (150 mg t.i.d.)
Study: 31681981
Drug: Palliative Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative Care Needs Rounds (monthly hour-long staff-only triage meetings)
Study: 30085075
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B at 100 mg/kg twice daily for 10 days
Study: 30085075
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B at 25 mg/kg twice daily for 10 days
Study: 28885428
Drug: Brief behavioral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief behavioral intervention during prenatal care visit (7‐ to 10‐minute in‐office intervention including a video and hygiene education using motivational interviewing, reminder calendar, and weekly text message reminders)
Study: 21335507
Drug: Lycopene (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene (10 μg/dL increase)
Study: 21335507
Drug: Lycopene (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene (10 μg/dL increase) in placebo arm
Study: 16954440
Drug: Markers of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Markers of hormone sensitivity (bcl2, ER, PgR)
Study: 15284501
Drug: Periradicular methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periradicular methylprednisolone (in combination with bupivacaine)
Study: 11773888
Drug: Basiliximab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basiliximab (20 mg i.v. bolus on days 0 and 4)
Study: 11773888
Drug: Antithymocyte globulin
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithymocyte globulin (ATG) (15 mg/day i.v. for up to 14 days)
Study: 8452344
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil suspension (20 mg/kg of body weight per day in two divided doses)
Study: 8452344
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V suspension (50 mg/kg/day in three divided doses)
Study: 3899250
Drug: Chemotherapy (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (n = 59)
Study: 3899250
Drug: Immunotherapy (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (n = 57)
Study: 21114380
Drug: Barnidipine up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barnidipine up to 20 mg
Study: 21114380
Drug: Hydrochlorothiazide (HCT)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCT) up to 25 mg
Study: 20128377
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg/d for 8 weeks
Study: 20128377
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (calcium antagonists, ACEI, diuretics, beta-receptor blocker for 8 weeks)
Study: 15183485
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam radiotherapy (EBRT) with daily RT in 3-Gy fractions, total dose of 21 Gy.
Study: 30829067
Drug: Web-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based cognitive behavioral therapy for insomnia (wCBT-I) coupled with general sleep education
Study: 31781700
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement with provisional or customised healing abutment
Study: 31781700
Drug: Horizontal implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horizontal implant position
Study: 22859712
Drug: Aliskiren (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (300 mg once daily)
Study: 17022982
Drug: Ovulation induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovulation induction in a chronic low-dose step-up FSH regimen
Study: 12620789
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of medial posting and custom-molding of foot orthotics
Study: 9272405
Drug: Otilonium bromide
Normalized name: otilonium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otilonium bromide 120 mg
Study: 9272405
Drug: Otilonium bromide
Normalized name: otilonium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otilonium bromide (combined doses of 80, 160, and 240 mg)
Study: 9272405
Drug: Otilonium bromide
Normalized name: otilonium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otilonium bromide (all doses)
Study: 7712918
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose cyclosporin A (CsA)
Study: 7712918
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide pulses (IV‐CTX)
Study: 26335915
Drug: Adjuvanted influenza
Normalized name: Influenza, adjuvanted, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted influenza vaccine (MF-59)
Study: 26335915
Drug: Nonadjuvanted influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadjuvanted influenza vaccine
Study: 23066663
Drug: Oral PUVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PUVA sol
Study: 18718735
Drug: Chemotherapy or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy or radiotherapy
Study: 14535966
Drug: Active nasal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active nasal continuous positive airway pressure (nCPAP) treatment
Study: 3571046
Drug: Ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 750 mg orally every 12 h on days 1‐7
Study: 3571046
Drug: Ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 750 mg orally every 12 h on days 6‐14
Study: 22974466
Drug: Rotarix™ (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotarix™ (two or three doses at 10 and 14 weeks)
Study: 22974466
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three doses at 6, 10, 14 weeks)
Study: 20608066
Drug: Cytoflavin tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin tablets
Study: 18207018
Drug: Non-specific immunomodulation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-specific immunomodulation therapy (IMT)
Study: 18207018
Drug: Non-specific immunomodulation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-specific immunomodulation therapy (IMT) in patients with no history of previous myocardial infarction (n=919)
Study: 18207018
Drug: Non-specific immunomodulation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-specific immunomodulation therapy (IMT) in patients with NYHA II heart failure (n=689)
Study: 12825173
Drug: GBS II-TT
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBS II-TT (3.6 micro g of CPS)
Study: 12825173
Drug: GBS III-TT
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBS III-TT (12.5 micro g of CPS)
Study: 12825173
Drug: Bivalent GBS
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent GBS II-TT/III-TT vaccine
Study: 12825173
Drug: GBS II-TT
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBS II-TT or GBS III-TT monovalent vaccines
Study: 10662983
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural analgesia (EA) with local anaesthetics (bupivacaine 0.125% or ropivacaine 0.2%) and fentanyl 4.5 microg/ml, flow rate 4-10 ml/h
Study: 10662983
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia (PCA) with piritramid (bolus 2.5 mg, lock out 15 minutes, maximum of 25 mg/4 h, no background infusion)
Study: 8861830
Drug: Prrikweg gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prrikweg gel
Study: 1634056
Drug: Intravenous vasoactive
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vasoactive intestinal polypeptide (VIP) at doses of 1.5, 3, and 5 pmol.kg‐1.min‐1
Study: 1634056
Drug: Beta-adrenergic agonist
Normalized name: Alpha-adrenergic and beta-adrenergic agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenergic agonist isoproterenol
Study: 31337441
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy (rESWT) combined with a specific rehabilitation program (RP)
Study: 26706862
Drug: Cyproheptadine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproheptadine (4 mg 3 times per day for 7 days)
Study: 21186535
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (Leep combined with drugs)
Study: 21186535
Drug: Secondary high-risk
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary high-risk HPV non-treatment group
Study: 21186535
Drug: Primary high-risk
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary high-risk HPV treatment group (Leep combined with drugs)
Study: 21186535
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy (Leep)
Study: 21186535
Drug: Surgical +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical + Drugs
Study: 12879275
Drug: Long-term antibiotic
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term antibiotic therapy with doxycycline
Study: 10188068
Drug: Immediate access
Normalized name: sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Immediate access to therapy
Study: 1942930
Drug: Intensified therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified therapy consisting of rotation of 6 non cross‐resistant drug combinations with 12 different agents.
Study: 1942930
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of intensive therapy for poor responders (children with more than 10% blasts in the BM on day 28).
Study: 7006118
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of cefuroxime plus 1 g of probenecid
Study: 7006118
Drug: 5 x
Normalized name: PAD,ABDOMINAL 5 X 9 STERILE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 x 10(6) units of benzyl penicillin plus 1 g of probenecid
Study: 7006118
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg of cefuroxime plus 1 g of probenecid
Study: 7006118
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g of cefuroxime alone
Study: 24424709
Drug: Intramuscular levomepromazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular levomepromazine
Study: 17327934
Drug: Esomeprazole 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 80 mg
Study: 15471182
Drug: Ganciclovir (Cymevene)
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir (Cymevene) for three months (combined intravenous and oral)
Study: 11577950
Drug: CHX‐Alc (0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHX‐Alc (0.2% chlorhexidine solution)
Study: 2636680
Drug: Dietary protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary protein restriction (DPR) group (0.4 to 0.6 g/kg/day)
Study: 25989868
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa 2 µg/kg
Study: 25989868
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa 10 µg/kg
Study: 15249347
Drug: beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-blocker therapy
Study: 11211198
Drug: CsA-SM (oil-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA-SM (oil-based formulation of cyclosporine)
Study: 2663319
Drug: Lacidipine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine (4 mg dose)
Study: 28755782
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 μg once daily)
Study: 29129436
Drug: Risedronate (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (35 mg once weekly)
Study: 27147514
Drug: recAP 200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: recAP 200, 500, 1000 or 2000 U/kg (single dose)
Study: 27147514
Drug: recAP 500
Normalized name: recAP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: recAP 500 or 1000 U/kg (multiple doses)
Study: 27147514
Drug: recAP (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: recAP (various doses)
Study: 22918614
Drug: Fosphenytoin sodium
Normalized name: Fosphenytoin Sodium
DrugBank: Fosphenytoin (DB01320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosphenytoin sodium 22.5 mg/kg at an infusion rate of 3 mg/kg/min
Study: 22918614
Drug: Fosphenytoin sodium
Normalized name: Fosphenytoin Sodium
DrugBank: Fosphenytoin (DB01320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosphenytoin sodium 30 mg/kg
Study: 8907587
Drug: Indomethacin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (25 mg, single oral dose)
Study: 8907587
Drug: Experimental compounds
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental compounds (CGP-28238, Dup-697, NS-398, SC-58125, L-745,337)
Study: 8907587
Drug: LPS (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS (100 mu g/mL)
Study: 6755682
Drug: Pressimmune (AHLG‐Behring)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pressimmune (AHLG‐Behring) at 30 mg/kg/bdw for 21 days
Study: 30554828
Drug: Nabiximols (oromucosal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabiximols (oromucosal spray containing 2.7 mg delta-9-tetrahydrocannabinol and 2.5 mg cannabidiol, self-titrated up to 12 actuations per 24 h for 6 weeks)
Study: 26031321
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of PAHs (single compounds or mixtures)
Study: 25100138
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (5 mL/s and 90 mAs)
Study: 25100138
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (3.5 mL/s and 135 mAs)
Study: 25100138
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (5 mL/s and 135 mAs)
Study: 25100138
Drug: Group D
Normalized name: Prostaglandin group D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D (3.5 mL/s and 90 mAs)
Study: 19176684
Drug: rATG induction
Normalized name: rATG
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rATG induction therapy
Study: 17696229
Drug: Dexrabeprazole 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexrabeprazole 10 mg
Study: 12165717
Drug: Lorazepam as
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorazepam as adjuvant therapy
Study: 9707190
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis with rtPA
Study: 433806
Drug: 36 g
Normalized name: ARBUTIN 0.36 g in 5 g CUTANEOUS LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 g nitrogen diet
Study: 29890150
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with concurrent thoracic radiotherapy (50 Gy) followed by resection and postoperative consolidation chemotherapy
Study: 25222841
Drug: Cabergoline treatment
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabergoline treatment
Study: 11453955
Drug: GH administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GH administration (1.80 +/- 0.24 IU/day) for 12 weeks
Study: 11453955
Drug: GH discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH discontinuation
Study: 5413950
Drug: Ergotamine tartrate
Normalized name: Ergotamine Tartrate
DrugBank: Ergotamine (DB00696)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ergotamine tartrate (0.25 mg. intravenously)
Study: 5413950
Drug: Ergometrine maleate
Normalized name: Ergometrine maleate
DrugBank: Ergometrine (DB01253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergometrine maleate (0.25 mg. intravenously)
Study: 28436015
Drug: 5% topical
Normalized name: BP 5% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% topical minoxidil solution applied twice daily to fingernails
Study: 16467096
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m2 (10‐minute i.v. infusion) on day 1 of a 21‐day cycle with folic acid and vitamin B12 supplementation
Study: 16467096
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m2
Study: 16467096
Drug: Pemetrexed chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed chemotherapy
Study: 12620606
Drug: Remifentanil (mu-opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (mu-opioid agonist) administered via computer-controlled infusion targeting plasma concentrations between 0 and 6 ng/ml.
Study: 8744657
Drug: Morphine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (2 mg loading dose, 0.5 mg boluses, 0.2 mg/h infusion)
Study: 8744657
Drug: Fentanyl (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (60 micrograms loading dose, 25 micrograms boluses)
Study: 8744657
Drug: Fentanyl plus
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl plus morphine (F/M group)
Study: 7020108
Drug: Penbutolol 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol 40 mg daily for 7 days
Study: 7020108
Drug: Penbutolol 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol 4 mg intravenous
Study: 15325894
Drug: Colposcopy done
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colposcopy done twice by a single examiner
Study: 11795343
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day of tamoxifen
Study: 9625100
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg Ca as calcium carbonate twice daily with meals for 6 months
Study: 9625100
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily with meals for 6 months
Study: 8043313
Drug: Intravenous pyridoxine
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pyridoxine (1 g dose)
Study: 23343224
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant systemic treatment
Study: 21605000
Drug: Metformin (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (n = 26)
Study: 21605000
Drug: Low-dose flutamide-metformin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose flutamide-metformin plus an oral contraceptive (PCOS women, n = 58)